Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06910163

Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO

Direct-to-angio approach from loCal hOspitals based on a PoInt-of-care bLOod Test for LVO (COPILOT) is a multi-center, prospective, cluster-randomized crossover trial that will evaluate if the triage assessment to thrombectomy puncture time is shorter after performing the LVOne testing compared to current management standards in patients with suspected large vessel occlusion.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Menonita Caguas

Caguas, PR, 00725, Puerto Rico

About this study

The COPILOT trial utilizes a cluster randomized crossover design within the Sistema de Salud Menonita (SSM) hospital network to evaluate if early detection of large vessel occlusion (LVO) stroke with a novel blood test can accelerate the time from triage assessment to thrombectomy puncture. It will unfold in three phases:

Phase 0 - Baseline Data Collection (3 months): Before the random allocation, all clusters undergo data collection on baseline characteristics and outcome measures to confirm/set a pre-intervention comparison ground. Phase 0 patients will receive the current standard of care. An interim analysis will check recruitment rates and explore the need for additional clusters for adequate study power.

Phase 1 - Intervention and Control (12 months): Clusters are randomized to either the intervention or control group, with the intervention arm implementing the LVOne test and the control arm continuing standard care without the LVOne test. Data analysts remain blinded to group allocation, while an interim analysis revisits recruitment and primary outcomes to assess whether additional clusters are required.

Phase 2 - Crossover (12 months): Clusters switch roles from Phase 1, allowing every cluster to experience both the intervention and control conditions, facilitating within-cluster comparisons. The nature of the intervention prevents the blinding of participants and staff.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 21 to 85 years old
  • Language: Speak and understand Spanish or English
  • Residence: Resident of Puerto Rico
  • Clinical presentation: Suspected acute stroke
  • Time of presentation: Monday to Friday, between 8:00 a.m. and 4:00 p.m.
  • Time of symptom onset: symptoms are known to have begun within the last 6 hours, OR last known to be well between 6 and 18 hours ago, confirmed by a reliable witness or healthcare professional

Exclusion criteria

  • Previous healthcare encounter:
  • Already assessed at another hospital, and ambulance admission is a transfer for continuing care OR
  • Received thrombolysis therapy before consent (e.g., tPA, alteplase)
  • Medical History: diagnosed with any of the following in the past 4 weeks: deep vein thrombosis (DVT), pulmonary embolism (PE), arterial embolism, stroke, transient ischemic attack (TIA), long bone fracture, major trauma, surgery under general anesthesia, or head injury requiring hospital admission within the last 4 weeks.
  • Modified Rankin Scale: Pre-stroke mRS ≥ 3
  • The patient is a pregnant woman
  • The patient is under legal custody or deprived of liberty in penitentiary institutions
  • The patient is unable to provide informed consent on their own and whose authorized legal representatives are unavailable in person or by telephone during recruitment

Treatment and study plan

Diagnostic standard of care

Diagnostic Test

Participants will receive the diagnostic standard of care: standard laboratory workup, non-contrast brain CT, brain CTA, brain CTP, or brain MRI.

LVOne Test

Diagnostic Test

Participants will receive the LVOne test, which will measure D-dimer and Glial Fibrillary Acidic Protein (GFAP) levels to diagnose acute stroke.

Primary outcomes

  1. Change in the time from triage assessment to thrombectomy puncture

    Time frame: 24 hours

    The difference in time from the participant triage assessment to thrombectomy puncture.

Secondary outcomes

  1. Time from spoke hospital triage assessment to LVOne test in intervention

    Time frame: 24 hours

    Difference in time from triage assessment to the performance of the LVOne test in the intervention group.

  2. Time from HUB hospital triage assessment to LVOne test in intervention

    Time frame: 24 hours

    The difference in time from the HUB hospital triage assessment to the performance of the LVOne test.

  3. Time from HUB hospital triage assessment to thrombectomy puncture

    Time frame: 24 hours

    The difference in time from the HUB hospital triage assessment to the thrombectomy puncture.

  4. Thrombectomy rate (proportion of treated LVO)

    Time frame: 24 hours

    The number of participants that received thrombectomy.

  5. Length of hospital stay

    Time frame: From date of randomization until the date of discharge or date of death from any cause while patient is in hospital, whichever came first, assessed up to 30 days

    The participant's hospitalization period.

  6. Length of ICU stay

    Time frame: From date of randomization until the date of discharge or date of death from any cause while patient is in hospital, whichever came first, assessed up to 30 days

    The participant's hospitalization period in the intensive care unit (ICU).

  7. Diagnostic accuracy for LVO detection

    Time frame: At the time of initial assessment and confirmed by diagnostic imaging within 24 hours

    The ability of the test to correctly identify large vessel occlusion (LVO) in patients with suspected acute ischemic stroke. Diagnostic accuracy will be assessed by comparing the test results to the reference imaging standards.

  8. Diagnostic accuracy for intracerebral hemorrhage detection

    Time frame: At the time of initial assessment and confirmed by diagnostic imaging within 24 hours

    The ability of the LVOne test to correctly detect intracerebral hemorrhage (ICH) in patients presenting with acute stroke symptoms. Diagnostic accuracy will be determined by comparing LVOne test results to diagnostic imaging.

  9. Modified Rankin Scale (mRS)

    Time frame: At the time of initial assessment, 24 hours, at discharge, 3 months, 6 months, and 12 months

    The modified Rankin Scale (mRS) is a measure of functional outcome assessing the degree of disability or dependence in daily activities. The scale ranges from 0 (no symptoms) to 6 (death).

Study contacts

Contact information is provided by the study sponsor or research team.

Maria M Garcia Perez

CONTACT

[email protected]

939-417-4432

Sponsors and collaborators

Lead sponsor

Juan Vicenty

Other

Collaborators

  • Mennonite Health System
  • University of Puerto Rico

Registry information

Official study title

Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO (COPILOT): an Effectiveness Cluster Randomized Crossover Trial

Acronym: COPILOT

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 4, 2025
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.